Molecular biologist Yali Dou, PhD, holder of the Marion and Harry Keiper Chair in Cancer Research and professor of medicine and cancer biology at the Keck School of Medicine of USC, has been elected a fellow of the American Association for the Advancement of Science (AAAS). She is one of seven USC faculty members in the 2025 cohort of new fellows. Dou, the associate director for basic research at USC Norris Comprehensive Cancer Center, is a recognized leader in the study of epigenetics, the mechanisms that enable the singular instructions in DNA to be expressed as myriad cell and tissue types. She has made major contributions to the fundamental understanding of a family of enzymes that plays a vital role in fetal development by altering the coiled chromatin, which packages DNA to fit in the chromosomes of a cell’s nucleus, so that genes are activated. Because mutations of the founding member of this family of enzymes can also spur leukemia, they are known as mixed-lineage leukemia proteins, or MLL. MLL enzymes are among the most frequently mutated genes in cancer.

Wearable mobile health technology could help people with Type 2 Diabetes (T2D) to stick to exercise regimes that help them to keep the condition under control, a new study reveals.

An international team publishing in the BMJ Open studied the behaviour of recently-diagnosed T2D patients in Canada and the UK as they followed a home-based physical activity programme, with some participants wearing a smartwatch paired with a health app on their smartphone.

The ‘Mobile Health Biometrics to Enhance Exercise and Physical Activity Adherence in Type 2 Diabetes (MOTIVATE-T2D) feasibility trial recruited participants aged 40-75 years, diagnosed with T2D within the previous 5-24 months and managing their condition through lifestyle modification alone or Metformin.

They discovered that MOTIVATE-T2D participants were more likely to start and maintain purposeful exercise at if they had the support of wearable technology. The study successfully recruited 125 participants with an 82% retention rate after 12 months.

Cancer remains a leading cause of death globally, with lung cancer being particularly lethal. Despite advancements in diagnostics and therapies, the five-year survival rates for advanced tumors have seen minimal improvement, largely due to therapeutic resistance. This resistance can be genetic or nongenetic, with the latter being less understood but increasingly recognized for its role in treatment failure. Non-genetic resistance is associated with resistant cancer cells that have innate or acquired drug resistance traits. These cells are often found in heterogeneous tumors and include cancer stem-like cells (CSCs), cells undergoing epithelial-to-mesenchymal transition (EMT), partial EMT cells, and drug-tolerant persisters (DTPs). NOTCH signaling plays a crucial role in tumorigenesis and therapeutic resistance, with its activation linked to drug resistance in various cancers.